CNS 18 - 11 
for both) and this clone has been approved by the FDA for use in our 
clinical studies. All batches of the GITKSVNA-producer cell lines used 
for injection into humans will have met FDA specifications for current 
clinical human gene therapy experiments in progress. 
For use in the current study, frozen and certified cell lines will be shipped 
to Memphis and thawed immediately prior to use (see Appendix A). 
4.0 ELIGIBILITY CRITERIA 
4.1 Inclusion Criteria 
1. >3 years and < 21 years 
2. PROGRESSIVE OR RECURRENT SUPRATENTORIAL GADOLINIUM 
ENHANCING BRAIN TUMOR OF ANY MALIGNANT HISTOLOGY, 
without lepto-meningeal tumor as documented spinal MRI and CSF 
cytology (when possible). 
3. Patients must be at least 3 months beyond completion of radiation therapy, 
and recovered from the acute toxicities associated with any prior 
chemotherapy. 
4. Histologic diagnosis previously established. 
5. Minimum tumor size 1.5 cm 3 ; maximum tumor size 5 cm 3 . 
6. Serum Creatinine < 2 x N or creatinine clearance > 80 ml/ min/ m 2 
7. Coagulation profile within normal range 
8. Absence of any acute viral, bacterial or fungal infection requiring specific 
therapy 
9. HIV Negative 
10. Not pregnant 
11. Platelet count > 100,000/mm 3 and absolute neutrophil count _>1, 000/mm 3 
12. Absence of any grade m/IV major organ dysfunction 
13. Kamofsky score >40 
14. Life expectancy > 2 months 
15. Informed Consent Obtained 
[314] 
Recombinant DNA Research, Volume 18 
